UNLABELLED: The aim of this study was to assess the relationships between both a marker of bone formation and a marker of bone turnover and age, sex, and pubertal stage in a group (n = 439) of healthy children and adolescents. These reference data should be instrumental in interpretation of results. INTRODUCTION: The skeletal system has high metabolic activity. In children, bone markers may be useful in diagnostics and treatment management of skeletal diseases but there could be difficulties with interpretation of results. Compared with adults, children have elevated bone marker levels due to high skeletal growth velocity and rapid bone turnover. Thus, valid age- and sex-specific reference data should be obtained for each pediatric population living in a particular climate and with a similar lifestyle. The aim of this study was to assess the relationships between both a marker of bone formation (procollagen type I N-terminal propeptide [PINP]) and a marker of bone turnover (osteocalcin [OC]) and age, sex, and pubertal stage in a group of healthy children and adolescents. METHODS: Four hundred thirty-nine healthy Caucasian children participated. Their height, weight, and pubertal stage were recorded. Fasting PINP and OC were measured using a morning blood sample. RESULTS: The highest levels of PINP were observed during the first year of life. There is no OC postnatal peak, but levels are higher than the adult reference interval throughout childhood. OC peaks with the pubertal growth spurt at second-third Tanner stage of breast development in girls and at second-third Tanner stage of genital development in boys. PINP peaks during second-third Tanner stage of breast development in girls and at third Tanner stage of genital development in boys. CONCLUSION: This study provides reference data for OC and PINP in healthy Caucasian children from a Central European population.

• MeSH
• Anthropometry MeSH
• Biomarkers blood   MeSH
• Child MeSH
• Infant MeSH
• Humans MeSH
• Adolescent MeSH
• Infant, Newborn MeSH
• Osteocalcin blood   MeSH
• Peptide Fragments blood   MeSH
• Sex Characteristics MeSH
• Child, Preschool MeSH
• Procollagen blood   MeSH
• Puberty blood   MeSH
• Reference Values MeSH
• Aging blood   MeSH
• Check Tag
• Child MeSH
• Infant MeSH
• Humans MeSH
• Adolescent MeSH
• Infant, Newborn MeSH
• Child, Preschool MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

An increase in procollagen type I amino-terminal propeptide (PINP) early after teriparatide initiation was shown to correlate with increased lumbar spine areal BMD and is a good predictor of the anabolic response to teriparatide. Few data exist correlating PINP and bone microstructure, and no data exist in patients on teriparatide following prior potent antiresorptive treatment. This exploratory analysis aimed to investigate the effects of teriparatide on cancellous bone microstructure and correlations of bone markers with microstructure in alendronate-pretreated patients. This was a post hoc analysis of changes in bone markers and three-dimensional indices of bone microstructure in paired iliac crest biopsies from a prospective teriparatide treatment study in postmenopausal women with osteoporosis who were either treatment-naïve (TN, n=16) or alendronate-pretreated (ALN, n=29) at teriparatide initiation. Teriparatide (20μg/day) was given for 24months; biopsies were taken at baseline and endpoint, and serum concentrations of PINP and type 1 collagen cross-linked C-telopeptide (βCTX) were measured at intervals up to 24months. In the TN and ALN groups, respectively, mean (SD) increases in three-dimensional bone volume/tissue volume were 105 (356)% (P=0.039) and 55 (139)% (P<0.005) and trabecular thickness 30.4 (30)% (P<0.001) and 30.8 (53)% (P<0.001). No significant changes were observed in trabecular number or separation. In the ALN patients, 3-month change of neither PINP nor βCTX correlated with indices of cancellous bone microstructure. However, 12-month changes in biochemical bone markers correlated significantly with improvements in bone volume/tissue volume, r=0.502 (P<0.01) and r=0.378 (P<0.05), trabecular number, r=0.559 (P<0.01) and r=0.515 (P<0.01), and reduction of trabecular separation, r=-0.432 (P<0.05) and r=-0.530 (P<0.01), for PINP and βCTX, respectively. We conclude that cancellous bone microstructure improved with teriparatide therapy irrespective of prior antiresorptive use.

• MeSH
• Alendronate therapeutic use   MeSH
• Bone Density Conservation Agents therapeutic use   MeSH
• Collagen Type I blood   MeSH
• Bone Density drug effects   MeSH
• Middle Aged MeSH
• Humans MeSH
• Peptide Fragments blood   MeSH
• Peptides blood   MeSH
• Osteoporosis, Postmenopausal drug therapy   MeSH
• Procollagen blood   MeSH
• Bone Remodeling drug effects   MeSH
• Aged MeSH
• Teriparatide therapeutic use   MeSH
• Cancellous Bone drug effects   MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Clinical Trial MeSH
• Multicenter Study MeSH
• Research Support, Non-U.S. Gov't MeSH

PURPOSE: The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis. METHODS: Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined. RESULTS: Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications. CONCLUSION: We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.

• MeSH
• Biomarkers blood   MeSH
• Risk Assessment methods   MeSH
• Bone Density Conservation Agents therapeutic use   MeSH
• Collagen Type I blood   MeSH
• Consensus MeSH
• Humans MeSH
• Osteoporotic Fractures prevention & control   etiology   MeSH
• Osteoporosis * diagnosis   physiopathology   drug therapy   blood   therapy   MeSH
• Peptide Fragments blood   MeSH
• Peptides blood   MeSH
• Procollagen blood   MeSH
• Bone Remodeling * physiology   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Consensus Development Conference MeSH
• Review MeSH

UNLABELLED: A 12-month morning teriparatide (TPTD) administration resulted in a larger increase in the lumbar spine bone mineral density (BMD) than the evening application. The results indicate that the response of bone cells to teriparatide treatment depends on dosing time. INTRODUCTION: The aim of this study was to assess the long-term effects of the morning vs. the evening teriparatide administration on BMD and bone turnover markers (BTMs) in postmenopausal osteoporosis. METHODS: Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening. The BMD and serum concentrations of C-terminal telopeptide of type I collagen, N-terminal propeptide of type I procollagen (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were measured at baseline, after 6 and 12 months. General linear model-repeated measurements were used to analyze the data. RESULTS: After 12 months, the lumbar spine BMD grew markedly (p < 0.001) with a significantly greater increase in the morning arm compared to the evening arm (9.1% vs. 4.8%, respectively, p < 0.05). The BMD at the distal radius significantly decreased (p < 0.001), with no differences between the arms. The BMD at proximal femur did not change significantly. After 6 months, the BTMs were significantly increased compared with baseline (p < 0.001). The increases in the evening arm vs. the morning arm, however, were more pronounced in PINP (+358% vs. +215%, respectively) and in TRAP 5b (+70% vs. +37%, respectively) (both p < 0.05). CONCLUSION: 12-month morning administration of TPTD resulted in a larger increase in the lumbar spine BMD than the evening application. The timing of TPTD administration may be important for its efficacy.

• MeSH
• Lumbar Vertebrae physiopathology   MeSH
• Biomarkers blood   MeSH
• Phosphates blood   MeSH
• Bone Density Conservation Agents administration & dosage   therapeutic use   MeSH
• Injections, Subcutaneous MeSH
• Isoenzymes blood   MeSH
• Collagen Type I blood   MeSH
• Bone Density drug effects   MeSH
• Acid Phosphatase blood   MeSH
• Middle Aged MeSH
• Humans MeSH
• Peptide Fragments blood   MeSH
• Peptides blood   MeSH
• Osteoporosis, Postmenopausal blood   drug therapy   physiopathology   MeSH
• Procollagen blood   MeSH
• Drug Administration Schedule MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Teriparatide administration & dosage   therapeutic use   MeSH
• Calcium blood   MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Randomized Controlled Trial MeSH

Cíl studie: Sledovat vliv opakovaných krevních odběrů a diety obohacené o železo na kostní metabolismus u samců potkanů kmene Wistar. Typ studie: Základní výzkum. Název a sídlo pracoviště: Vivárium a radioizotopové laboratoře, LF UK Hradec Králové, Ústav klinické biochemie a diagnostiky, Fakultní nemocnice Hradec Králové. Materiál a metody: Potkani byli po dobu 8 týdnů krmeni standardní laboratorní dietou (SLD, 27 mg Fe/kg diety) nebo dietou obohacenou o železo (FE, 400 mg Fe/kg diety). Týdně byl proveden odběr (w) 0,5 ml krve/100 g tělesné hmotnosti, celkem 8krát. Skupiny: 1. kontrolní skupina SLD; 2. kontrolní skupina FE; 3. SLD-w; 4. FE-w. V krvi byl stanoven krevní obraz, respiratorní vzplanutí (RB), v séru koncentrace prohepcidinu a železa, v játrech koncentrace železa. Z kostních ukazatelů jsme stanovili: osteokalcin (OC), N-terminální propeptid prokolagenu typu I (PINP), C-terminální telopeptid kolagenu typu I (CTx) a tartát-rezistentní kyselou fosfatázu (TRACP). Byla změřena kostní minerální hustota (BMD). Výsledky: U skupin s krevními odběry bylo vyšší spontánní RB a železo v séru, naopak došlo k poklesu sérového prohepcidinu, hemoglobinu i železa v játrech ve srovnání s SLD a FE, u FE-w bylo také vyšší stimulované RB. Hodnoty PINP (p < 0,05), CTx (p < 0,05) a TRAP (p < 0,05) vzrostly u SLD-w ve 3. týdnu a u FE-w v 1. týdnu, hodnoty OC (p < 0,05) vzrostly pouze u FE-w v 1. týdnu, poté všechny hodnoty poklesly na hodnoty SLD a FE. BMD vzrostla po odběrech v bederní a ocasní oblasti (p < 0,01). Závěr: Opakované krevní odběry a dieta obohacená o železo vedly k vyšší reaktivitě buněk makrofágového systému, k vyšší aktivitě osteoklastů, ke stimulaci osteoblastů s následným pozitivním vlivem na kvalitu kostní tkáně. Klíčová slova: odběr krve, železo, osteokalcin, N-terminální propeptid prokolagenu typu I, C-terminální telopeptid kolagenu typu I.

Objective: We studied the infl uence of repeated blood withdrawals and iron enriched diet on biochemical markers of bone metabolism in male Wistar rats. Design: Basic research. Settings: Radioisotope Laboratories and Vivarium, Charles University, Medical Faculty, Hradec Kralove, Institute of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Kralove. Material and Methods: Rats were fed for 8 weeks with standard laboratory diet (SLD, 27mg Fe/kg diet) or iron enriched diet (FE, 400 mg Fe/kg diet) and had blood withdrawals (w) 0.5 ml/100 g body weight, 8 times. Animals were divided into 4 groups: 1. Control group SLD; 2. Control group FE; 3. SLD-w; 4. FE-w. The following items were assessed in blood; haemoglobin concentration and respiratory burst (RB), iron stores in liver tissue. In serum were evaluated prohepcidin, iron and bone metabolism markers: osteocalcin (OC), N-terminal propeptid of procollagen I (PINP), C-terminal telopeptide of collagen I (CTx) and tartrate resistant acid phosphatase (TRACP). Bone mineral density (BMD) was measured. Results: Spontaneous RB and iron in serum increased in animals with repeated blood withdrawals, but serum prohepcidin, haemoglobin concentration and iron in liver decreased vs. SLD and FE, but in FE-w animals increased stimulated RB, too. Values of PINP (p < 0.05), CTx (p < 0.05) and TRAP (p < 0.05) increased by SLD-w in 1st week and by FE-w in 3rd week, values of OC (p < 0.05) increased only by FE-w, but then all these values decreased to values of SLD and FE. BMD increased by blood withdrawals in femur (p < 0.01) and lumbar part (p < 0.01). Conclusion: Repeated blood withdrawals and iron enriched diet contributed to stimulation reactivity of scavenger cells, elevation activity of osteoclast, stimulation of osteoblast with subsequent positive effect on quality of bone tissue. Key words: blood withdrawal, iron, osteocalcin, N-terminal propeptide of procollagen I, C-terminal telopeptide of collagen I.

• MeSH
• Iron, Dietary administration & dosage   MeSH
• Animal Experimentation MeSH
• Financing, Organized MeSH
• Collagen Type I blood   metabolism   MeSH
• Bone and Bones metabolism   drug effects   MeSH
• Blood metabolism   drug effects   MeSH
• Metabolism MeSH
• Osteocalcin blood   metabolism   MeSH
• Rats, Wistar MeSH
• Statistics as Topic MeSH
• Animals MeSH
• Check Tag
• Male MeSH
• Animals MeSH

OBJECTIVE: Statins have been widely used for the treatment of hypercholesterolemia, and recent studies have shown that these drugs also affect bone metabolism. The aim of this experiment was to follow the effect of atorvastatin on bone metabolism in male albino Wistar rats. METHODS: Our study was carried out on 16 rats (240 +/- 10g) which were randomly divided into 2 groups of 8 animals. The control group (CO) was given aqua pro injectione (0.2 mL/100 g BW; gavage) and the experimental group atorvastatin suspension (AT; 0.3 mg in 0.2 mL aqua pro inj./100 g BW; gavage) daily for 8 weeks. We examined serum markers of bone turnover using ELISA - C-terminal crosslinking telopeptide of type I collagen (CTX-I), total osteocalcin (total OC), procollagen type I N propeptide (PINP) and bone alkaline phosphatase (bone ALP). We investigated bone morphogenetic protein-2 (BMP-2) in the proximal tibia using Western blot analysis. Additionally, we measured bone mineral density (BMD). The femurs were used for a three-point bending test and compression test of the femoral neck. RESULTS: After 8 weeks of atorvastatin administration, a significant decrease was found in serum level of bone ALP to 30% vs. CO (p = 0.005). PINP, CTX-I and OC did not change significantly. The expression of BMP-2 was increased. There were no significant differences in BMD measurements, three-point bending test or compression test of the femoral neck. CONCLUSIONS: Our results suggest that atorvastatin has a positive effect on bone metabolism in rats by maintenance of BMD and the biomechanical characteristics of bone. Atorvastatin influenced bone metabolism by decreasing bone ALP, and probably in consequence increasing expression of BMP-2 in rats.

• MeSH
• Absorptiometry, Photon MeSH
• Alkaline Phosphatase metabolism   MeSH
• Biomarkers MeSH
• Biomechanical Phenomena MeSH
• Electrophoresis, Polyacrylamide Gel MeSH
• Collagen Type I metabolism   MeSH
• Bone and Bones drug effects   metabolism   MeSH
• Bone Density drug effects   MeSH
• Bone Morphogenetic Protein 2 metabolism   MeSH
• Rats MeSH
• Heptanoic Acids pharmacology   MeSH
• Osteocalcin metabolism   MeSH
• Osteoprotegerin metabolism   MeSH
• Peptide Fragments metabolism   MeSH
• Rats, Wistar MeSH
• Protein Prenylation MeSH
• Procollagen metabolism   MeSH
• Pyrroles pharmacology   MeSH
• Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology   MeSH
• Blotting, Western MeSH
• Animals MeSH
• Check Tag
• Rats MeSH
• Male MeSH
• Animals MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

The study aimed at evaluating the relation of 7 parameters associated with the internal biological properties of myeloma cells and the bone marrow microenvironment to multiple myeloma (MM) stages, distinguishing its initial/asymptomatic phase from monoclonal gammopathy of undetermined significance (MGUS) and assessing their relation to myeloma prognosis. In the studied group comprising 286 individuals (89 MGUS and 179 MM patients), statistically significant differences (Mann-Whitney test) between MGUS and MM at the time of diagnosis were found in the serum levels of HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor), ICTP (intercellular - carboxy-terminal telopeptide of type I collagen), PINP (procollagen type I N-terminal propeptide), OPG (osteoprotegerin) and syndecan-1/CD138, but not in Fas. Multivariate analysis (logistic regression) revealed an unsatisfactory potential of all the 7 studied indicators to discriminate between MGUS and MM. A deeper analysis showed statistically significant differences between MGUS and the initial/asymptomatic phase of MM (stage 1 according to the International Staging System) only in the cases of syndecan-1 (p=0.001) and Fas (p=0.008). The assessment of initial values of HGF, VEGF, ICTP, PINP, OPG, syndecan-1 and Fas showed a statistically significant relation (log rank test) to the overall survival (OS) in a group of 132 patients treated with conventional chemotherapy only in the cases of syndecan-1 (p=0.0002) and Fas (p=0.018), but in none of the investigated parameters in a group of 74 patients treated with HDT/ASCT (high-dose therapy/autologous stem cell transplantation). The analysis showed that, despite significant differences in serum levels of 6 of the 7 studied parameters found between MGUS and MM, none of the markers may be included in the spectrum of indicators used to distinguish the two conditions. Despite the positive relation, especially of syndecan-1 and, to a lesser extent, of Fas to the OS in patients treated with conventional chemotherapy, these prognostic factors are not applicable to HDT/ASCT.

• MeSH
• Diagnosis, Differential MeSH
• Adult MeSH
• Enzyme-Linked Immunosorbent Assay MeSH
• Hepatocyte Growth Factor blood   MeSH
• Collagen Type I MeSH
• Middle Aged MeSH
• Humans MeSH
• Multiple Myeloma blood   diagnosis   MeSH
• Monoclonal Gammopathy of Undetermined Significance blood   diagnosis   MeSH
• Biomarkers, Tumor blood   MeSH
• Osteoprotegerin blood   MeSH
• Peptide Fragments blood   MeSH
• Peptides MeSH
• Prognosis MeSH
• Procollagen blood   MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Neoplasm Staging MeSH
• Syndecan-1 blood   MeSH
• Vascular Endothelial Growth Factor A blood   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

Juvenile idiopathic arthritis (JIA) is an inflammatory disease associated with bone loss and low bone mineral density (BMD). The treatment involves disease-modifying antirheumatic drugs, glucocorticoids (GCs) and biological agents. The aim of this study was to evaluate effects of 12-month therapy with the anti-tumor necrosis factor alpha (anti-TNFα) preparations on bone mineral density (BMD) and biochemical turnover markers (BTM) in adult patients with JIA who were previously either treated or not treated with glucocorticoids (GC) and to assess effects of the discontinuation of GCs on their bone status. Nineteen adult patients (12 women, 7 men) aged 18-33 years with active JIA were prospectively enrolled to receive the anti-TNFα therapy (infliximab, etanercept or adalimumab). BMD and BTMs were determined at baseline and 1-year follow-up. The anti-TNFα therapy resulted in a significant reduction in disease activity score 28 (DAS28) and C-reactive protein (CRP) and a significant increase in BMD at the lumbar spine and total body and in serum N-terminal propeptide of type I procollagen (PINP, marker of bone formation). No significant changes in serum beta C-terminal telopeptide of type I collagen (βCTX, marker of osteoclastic bone resorption) and osteocalcin (marker of bone remodeling) were found. A significant negative correlation was observed between the change in the DAS28, CRP and serum PINP. The change in serum PINP concentrations positively correlated with the change in lumbar spine BMD. A significant increase in serum PINP was observed only in patients discontinuing GCs during the anti-TNFα treatment. After the initiation of the anti-TNFα therapy in young adults with JIA, the increase in new bone formation can be explained by discontinuation of GCs administration as the patients with the largest reduction in DAS28 and CRP probably are the ones most likely to stop GC.

• MeSH
• Antirheumatic Agents pharmacology   therapeutic use   MeSH
• Biomarkers blood   MeSH
• C-Reactive Protein metabolism   MeSH
• Adult MeSH
• Antibodies, Monoclonal, Humanized pharmacology   therapeutic use   MeSH
• Immunoglobulin G pharmacology   therapeutic use   MeSH
• Arthritis, Juvenile blood   drug therapy   radiography   MeSH
• Collagen Type I blood   MeSH
• Bone and Bones drug effects   radiography   MeSH
• Bone Density drug effects   MeSH
• Humans MeSH
• Adolescent MeSH
• Antibodies, Monoclonal pharmacology   therapeutic use   MeSH
• Osteocalcin blood   MeSH
• Procollagen blood   MeSH
• Receptors, Tumor Necrosis Factor therapeutic use   MeSH
• Bone Remodeling drug effects   MeSH
• Tumor Necrosis Factor-alpha antagonists & inhibitors   MeSH
• Treatment Outcome MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Adolescent MeSH
• Male MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

BACKGROUND: We hypothesized that with the administration of teriparatide (TPTD) treatment at different times, we would be able to modify the physiological circadian rhythm of bone turnover. METHODS: The concentration of serum C-terminal telopeptide of collagen type I (βCTX), serum N-terminal propeptide of procollagen type I (P1NP), serum ionized calcium (iCa), and plasma PTH were measured every 3 h over a 24 h period in 14 postmenopausal osteoporotic women (aged 72.4±9.3 years) treated with 20 μg TPTD for long term, given at different times of the day. General linear model-repeated measurements (GLM RM) were performed to analyze the circadian rhythms as well as intergroup comparisons. RESULTS: GLM-RM for both related groups showed a significant influence of time of day on all measured variables except P1NP. The analysis for each group separately provided a powerful model for βCTX (P<0.001, η(2)=0.496), serum iCa (P<0.001, η(2)=0.423), plasma PTH (P<0.001, η(2)=0.283), and serum PINP (P<0.001, η(2)=0.248). While the evening TPTD treatment showed a marked circadian rhythm for serum βCTX, the morning TPTD treatment rather suggested circasemidian rhythm. The P1NP rhythm followed a much smaller amplitude of the rhythm than βCTX. Changes in serum iCa were positively related to changes in serum βCTX (P<0.001) and negatively related to changes in PTH (P<0.001). CONCLUSION: Timing of TPTD administration may significantly change the 24 h variation in bone turnover markers as well as calcium-parathyroid axis in postmenopausal osteoporotic women.

• MeSH
• Circadian Rhythm drug effects   MeSH
• Bone Density Conservation Agents therapeutic use   MeSH
• Bone Density drug effects   MeSH
• Middle Aged MeSH
• Humans MeSH
• Osteoporosis, Postmenopausal drug therapy   physiopathology   MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Teriparatide therapeutic use   MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

OBJECTIVES: Our aim was to correlate serum levels of selected markers of bone metabolism and bone marrow microenvironment to cytogenetic changes in patients with multiple myeloma (MM). METHODS: We assed cytogenetic changes in 308 patients and correlated them with the following levels of bone marrow metabolism: thymidine kinase (TK), β2-microglobulin (b-2-m), Dickkopf-1 protein (DKK-1), C-terminal telopeptide collagen-I (ICTP), N-terminal propeptide of type I procollagen (PINP), receptor for interleukin 6 (rIL-6), vascular cell adhesive molecule-1 (VCAM), soluble intercellular adhesion molecule-1, osteoprotegerin (OPG), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), syndecan-1 (SYN-1) and Fas antigen. RESULT: Individuals with delRB1 had lower levels of OPG (M = 7.39 vs. 5.46 pmol/L, p = .025) and VEGF (M = 304 vs. 196 pg/ml; p = .036). t(14;16) was associated with higher β2m levels (M = 7.59 vs. 4.13 mg/L; p = .022) and lower DKK-1 levels (M = 4465 ng/L vs. 12,593). The presence of 1q21 gain was associated with higher levels of TK (M = 100.0 vs. 11.0 IU/L, p = .026) and lower levels of PINP (M = 49.3 vs. 67.4 mg/L, p = .030). CONCLUSIONS: Our analysis has shown, some cytogenetic changes, especially delRB1, t(14;16) and 1q21gain, which affect the components of the cytokine network in multiple myeloma.

• MeSH
• Biomarkers MeSH
• Cytogenetic Analysis MeSH
• Bone Marrow metabolism   MeSH
• Humans MeSH
• Multiple Myeloma * diagnosis   genetics   MeSH
• Tumor Microenvironment MeSH
• Vascular Endothelial Growth Factor A MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH